Advocates Requested Expanded Weight Loss Drug Coverage
New Mexico health groups asked for expanded access to GLP-1 treatments through the state Medicaid program.
Updated on Oct. 9, 2026 in Weight Loss
Live Poll
Should state Medicaid programs cover weight loss drugs for all eligible patients?
Five national health organizations have sent a letter to Governor Michelle Lujan Grisham urging the state to broaden its Medicaid coverage for weight loss medications. The push aims to address significant health disparities tied to obesity and related conditions across New Mexico.
Why it matters
Advocates argue that broader coverage would help reduce long-standing obesity-related healthcare inequities for the state population. The proposal reflects an effort to manage the rising demand and costs associated with obesity care in public health systems.
Official reports indicate New Mexico Medicaid spending on Ozempic reached $38.7 million in 2025, marking a 34% increase over 2024 and doubling the total from 2023. The impact of expanded coverage on patient health outcomes remains to be seen.
The players
Michelle Lujan Grisham
The Governor of New Mexico who received the formal request for Medicaid expansion.
American Diabetes Association
A national health organization focused on reducing the burden of diabetes through research and advocacy.
The details
GLP-1 medications like Ozempic mimic hormones that regulate appetite and blood sugar, helping to manage obesity and Type 2 diabetes. The state Medicaid program acts as the primary gatekeeper for these therapies, currently determining which patient populations qualify for coverage. Expanding access would change how these prescriptions are funded and distributed to residents covered by the state plan.
Timeline
2023: New Mexico Medicaid spending baseline.
2024: Baseline for the annual spending increase calculation.
2025: Total spending on Ozempic reached $38.7 million.
October 1, 2026: Advocacy groups submitted a formal request for coverage expansion.
Health Landscape
This request follows the national trend of surging Medicaid expenditures for GLP-1 medications observed over the last three years. It reflects the broader tension between meeting rising clinical demand for obesity care and managing state-level budgetary constraints.
If you are covered by New Mexico Medicaid and managing obesity or Type 2 diabetes, keep an eye on official state health updates regarding coverage criteria. It is worth discussing your current treatment options and potential changes to plan access with your physician.
The takeaway
The move to expand coverage highlights the growing focus on obesity as a critical component of chronic disease management. Consider tracking the availability of newer treatment guidelines and speaking with a primary care provider about how current state coverage policies affect your care options.
Further reading
Learn more about the latest developments in Weight Loss options and coverage policies.
Source note: This article includes information reported by Santa Fe New Mexican.
Live Poll
Should state Medicaid programs cover weight loss drugs for all eligible patients?
